cabozantinib,atezolizumab
exelixis,roche
['blcsm', 'cabozantinib', 'urothelial']
dr. pal reported remarkable activity for combo atezo+cabozantinib in advanced urothelial ca: tumor regressions reported in over half pts (62-74%) including those who are cisplatin-eligible/ineligible and also in pts pretreated with ici #asco22 #blcsm
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement